Allarity Therapeutics (ALLR) Regains Nasdaq Compliance

Allarity Therapeutics, Inc. (NASDAQ: ALLR) today announced that it has received formal written notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”) that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).

This confirmation follows the Company’s successful efforts to cut operation costs and improve its balance sheet, including raising new equity and reducing outstanding liabilities. As a result, Allarity Therapeutics now meets the stockholders' equity requirement of at least $2.5 million.

Thomas Jensen, CEO of Allarity Therapeutics, stated, “We are very pleased to announce that Allarity has regained compliance with Nasdaq's equity requirement. During our panel hearing with Nasdaq in February this year, we presented a strategic plan to achieve this goal, and I am satisfied to note that we have successfully delivered on our commitments and received formal confirmation from Nasdaq. This allows us to continue focusing on our mission to advance our lead asset, stenoparib, toward regulatory approval with the aim of bringing this promising therapy to patients in need of new treatment options for advanced ovarian cancer.”

As part of the compliance confirmation, Allarity Therapeutics will be subject to a mandatory panel monitor for one year.

As announced in an earlier press release, the Company intends to provide a more comprehensive clinical update in the near future to share more details on the progress made following the early conclusion of its Company's Drug Response Predictor (DRP^®) guided Phase 2 trial of stenoparib in advanced, recurrent ovarian cancer.

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• Solowin Holdings unit signs non-binding MOU with EvolveQ on AI and quantum
• Costco August net sales rise 9.9% to $23.70 billion